Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Abstract Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+), HER2-negative breast cancer. Here,...

Full description

Bibliographic Details
Main Authors: Richard Buus, Zsolt Szijgyarto, Eugene F. Schuster, Hui Xiao, Ben P. Haynes, Ivana Sestak, Jack Cuzick, Laia Paré, Elia Seguí, Nuria Chic, Aleix Prat, Mitch Dowsett, Maggie Chon U. Cheang
Format: Article
Language:English
Published: Nature Portfolio 2021-02-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00216-w

Internet

https://doi.org/10.1038/s41523-021-00216-w

Similar Items